In both ALL and CML, CCN1 enhances leukemic cell survival in vitro by decreasing apoptosis through enhanced BCL2 expression via the NF-κB pathway (Song et al. 2019; Zhu et al. 2016). Here, CCN1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.